Rocket Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Rocket is a clinical-stage gene-therapy company with no approved products and no product revenue. Financial amounts below are in millions of dollars unless otherwise noted.
Financial results and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $41.4 | $24.5 | $72.2 | $52.8 |
| General and administrative expense | $12.9 | $9.5 | $24.6 | $20.4 |
| Net loss | $54.4 | $34.5 | $97.4 | $74.7 |
| Net loss per share | $0.83 | $0.55 | $1.50 | $1.20 |
Operating margin and gross margin are not meaningful because the company reported no revenue. R&D and G&A expense increases drove the larger loss. Q2 R&D rose $16.8 million, mainly from manufacturing and development costs, higher R&D compensation, and laboratory supplies. Q2 G&A rose $3.3 million, including commercial-preparation, staffing, and legal costs.
- Cash, cash equivalents, and investments: $321.4 million at June 30, 2022, including $187.5 million of cash and equivalents and $133.8 million of investments; down from $388.7 million at December 31, 2021.
- Cash flows, first six months: $78.3 million used in operations, versus $62.8 million in 2021; $15.8 million provided by investing activities; and $17.3 million provided by financing, primarily net ATM proceeds.
- Runway: Management expected available resources to fund operating expenses and capital expenditures into the first half of 2024.
- Balance sheet: Total assets were $431.9 million and total liabilities $44.2 million. Current liabilities were $24.3 million. Finance lease liabilities totaled $20.9 million; operating lease liabilities totaled $1.3 million. The filing reports no material off-balance-sheet arrangements.
Material developments and outlook
- Rocket sold about 1.3 million shares through its at-the-market program for $17.8 million gross and $17.3 million net proceeds. The program authorizes up to $200 million of sales, at the company’s discretion.
- RP-L102 (Fanconi anemia): Management reported that the Phase 2 study’s primary endpoint had been achieved, based on interim data. Further data were expected in Q4 2022, and BLA planning had begun.
- RP-L201 (severe LAD-I): All nine treated patients were reported alive and clinically stable at the cited data cutoff. Rocket had begun FDA discussions on BLA plans and anticipated filing in the first half of 2023.
- RP-L301 (PKD): Two adult patients had sustained improvements in hemoglobin and remained transfusion-independent after engraftment, per interim data. Pediatric enrollment was ongoing; additional data were expected in Q4 2022.
- RP-A501 (Danon disease): The company reported encouraging interim observations, but the program has important safety history. After a serious complement-mediated TMA event in a high-dose patient, FDA placed the study on clinical hold in 2021; the hold was lifted in August 2021. Rocket is focusing on the lower dose and has enhanced immunosuppression and patient-selection measures. Early pediatric efficacy data were expected in Q3 2022, with FDA study-design discussions and Phase 2 planning anticipated in Q4 2022, subject to data.
- Rocket discontinued its sponsored RP-L401 clinical evaluation in December 2021 and returned the program to academic innovators, reallocating resources to other programs.
- Management expected R&D spending to increase as programs advance and manufacturing and clinical-development work continues. The company warned that additional financing may be needed longer term; equity financing could dilute shareholders, while debt could impose restrictive terms.
Risks, contingencies, and other items
Key risks include clinical and regulatory uncertainty, trial enrollment or execution delays, manufacturing and supply challenges, intellectual-property protection, competition, and the company’s dependence on future financing. Management noted capital-market volatility could impair access to funding. The filing reports an ongoing New York City audit of biotechnology credits for tax years 2018–2020; it does not state a clear potential financial exposure. The company said it was not party to litigation expected to have a material adverse effect. Disclosure controls were assessed as effective at a reasonable-assurance level, with no material changes in internal control reported.
Important facts for investors to verify
- Whether subsequent clinical data support the reported RP-L102 endpoint and the anticipated BLA path.
- RP-L201 regulatory requirements and the timing and feasibility of the anticipated first-half 2023 BLA filing.
- RP-A501’s safety profile at the selected dose, including complement-related events, and progress toward FDA-agreed Phase 2 plans.
- Actual cash burn, clinical and manufacturing spending, ATM sales, and whether the stated runway remains achievable.
- The outcome of the New York City tax-credit audit and any later disclosure of a potential liability.